VCP
ALPN

Vista Capital Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

Vista Capital Partners’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,304
Closed -$152K – 76
2021
Q1 		$152K Sell
14,304
-20,000
-58% -$249K 0.02% 65
2020
Q4 		$432K Buy
+34,304
New +$337K 0.07% 40

Other funds holding ALPN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vista Capital Partners's ALPN Position: Q2 2021 in Review

Vista Capital Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2021, closing a stake of 14,304 shares — an estimated $152K sold.

Vista Capital Partners first reported a position in ALPN in Q4 2020 and held it in 2 quarters. The position peaked at $432K in Q4 2020. 47 funds tracked by Wall St. Rank hold ALPN as of Q2 2021.

  • Vista Capital Partners reported no remaining Alpine Immune Sciences Inc position as of Q2 2021 after selling out during the quarter.
  • Vista Capital Partners sold 14,304 Alpine Immune Sciences Inc shares in Q2 2021, an estimated $152K.
  • Vista Capital Partners first reported a position in Alpine Immune Sciences Inc in Q4 2020 and held it in 2 quarters.
  • Vista Capital Partners's Alpine Immune Sciences Inc position peaked at $432K in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2021.

Based on Vista Capital Partners's 13F filing for Q2 2021, filed 9 Aug 2021.